Is CMMB or CNTA more undervalued in 2026?

CirclFi compares Chemomab Therapeutics Ltd. (CMMB) and Centessa Pharmaceuticals plc (CNTA) using 13 institutional-grade valuation models. CMMB has a Quality of Company score of 1.9/10 while CNTA scores 5.9/10.

Which is a better buy — CMMB or CNTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CMMB and CNTA valuations compare?

CMMB at $2.07 and CNTA at $39.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CMMB vs CNTA Valuation Comparison 2026 — Intrinsic Value Analysis

CMMB

Biotechnology

Chemomab Therapeutics Ltd.

Quality

1.9

out of 10

Value Trap

SAFE

Price

$2.07

Last close

Models

8/13

Active

CNTA

Biotechnology

Centessa Pharmaceuticals plc

Quality

5.9

out of 10

Value Trap

SAFE

Price

$39.81

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	CMMB Fair Value	CMMB Upside	CNTA Fair Value	CNTA Upside
Bayesian DCF	Intrinsic	$0.55	-73.5%	$11.91	-70.1%
Earnings Power Value	Intrinsic	—	—	$16.41	-58.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$0.07	-96.7%	$0.01	-100.0%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CMMB vs CNTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CMMB vs CNTA — Which Stock Is More Undervalued?

CNTA scores higher with a 5.9/10 quality rating vs CMMB's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Chemomab Therapeutics Ltd. (CMMB) and Centessa Pharmaceuticals plc (CNTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CMMB currently trades at $2.07 with a QOC of 1.9/10, while CNTA trades at $39.81 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).